Quest Diagnostics
DGX

Quest Diagnostics (DGX) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
BarclaysMaintainedOverweight$260.00 from $250.00Oct 7, 2026
Truist SecuritiesMaintainedHold$260.00 from $250.00Sep 21, 2026
UBSMaintainedNeutral$245.00 from $232.00Sep 8, 2026
JP MorganMaintainedNeutral$250.00 from $220.00Jul 28, 2026
BairdMaintainedNeutral$255.00 from $236.00Jul 24, 2026
BarclaysMaintainedOverweight$250.00 from $230.00Jul 24, 2026
Truist SecuritiesMaintainedHold$250.00 from $225.00Jul 24, 2026
MizuhoMaintainedOutperform$260.00 from $235.00Jul 24, 2026
UBSMaintainedNeutral$232.00 from $220.00Jul 24, 2026
BairdMaintainedNeutral$236.00 from $232.00Jul 13, 2026
Truist SecuritiesMaintainedHold$225.00 from $220.00Apr 22, 2026
BarclaysMaintainedOverweight$230.00 from $225.00Apr 22, 2026
BairdMaintainedNeutral$229.00 from $224.00Apr 22, 2026
UBSMaintainedNeutral$220.00 from $210.00Apr 22, 2026
Evercore ISI GroupMaintainedIn-Line$210.00 from $220.00Apr 8, 2026
MizuhoMaintainedOutperform$235.00 from $210.00Feb 12, 2026
JefferiesMaintainedBuy$220.00 from $215.00Feb 11, 2026
Evercore ISI GroupMaintainedIn-Line$220.00 from $190.00Feb 11, 2026
BarclaysMaintainedOverweight$225.00 from $210.00Feb 11, 2026
UBSMaintainedNeutral$210.00 from $190.00Feb 11, 2026

Frequently asked questions

  • What is the latest analyst rating on DGX?

    On Oct 7, 2026, Barclays maintained Quest Diagnostics at Overweight with a price target of $260.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.